Hadley Morgan, Halliday Alicia, Stone James M
Brighton and Sussex Medical School, University of Sussex, Brighton, UK.
J Psychoactive Drugs. 2025 Jan-Mar;57(1):47-53. doi: 10.1080/02791072.2023.2287081. Epub 2023 Nov 27.
Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incidence and prevalence. HPPD may be more common in those with trait neuroticism. In this study, we invited hallucinogen and other drug users to complete an online questionnaire about their use of hallucinogens, their experience of HPPD symptoms, and their trait neuroticism and mental health symptoms. We received 802 responses with 415 of these containing adequate data for further analysis. 39.7% of responders reported symptoms corresponding to Type I HPPD, and 4.3% reported symptoms corresponding to Type II HPPD. We found no significant difference between neuroticism scores for participants with or without HPPD. Individuals with Type II HPPD were more likely to report mental health symptoms including anxiety, obsessional thoughts, paranoia, hypochondria and panic attacks ( < .05). We also found that individuals with Type II HPPD were more likely to report the use of 25I-NBOMe, dextromethorphan, nitrous oxide and benzodiazepines ( < .05). 47.3% of participants had never tested their drugs, making the attribution of HPPD severity to specific drugs difficult. Further work into the development of HPPD is required, particularly with the rise of hallucinogens as potential treatments for depression and other mental illnesses.
致幻剂持续性感知障碍(HPPD)在致幻剂使用者中被认为较为罕见,尽管关于其发病率和患病率的报告相互矛盾。HPPD在具有神经质特质的人群中可能更为常见。在本研究中,我们邀请致幻剂及其他药物使用者完成一份在线问卷,内容涉及他们对致幻剂的使用情况、HPPD症状体验、神经质特质及心理健康症状。我们共收到802份回复,其中415份包含足够数据用于进一步分析。39.7%的回复者报告有符合I型HPPD的症状,4.3%报告有符合II型HPPD的症状。我们发现有或无HPPD的参与者在神经质得分上无显著差异。II型HPPD患者更有可能报告包括焦虑、强迫观念、偏执、疑病症和惊恐发作在内的心理健康症状(<0.05)。我们还发现,II型HPPD患者更有可能报告使用过25I-NBOMe、右美沙芬、一氧化二氮和苯二氮䓬类药物(<0.05)。47.3%的参与者从未对其药物进行过检测,这使得将HPPD严重程度归因于特定药物变得困难。需要进一步研究HPPD的发展情况,尤其是随着致幻剂作为治疗抑郁症和其他精神疾病的潜在药物的兴起。